Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

EVELO BIOSCIENCES, INC.

(EVLO)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/13/2022 01/14/2022 01/18/2022 01/19/2022 01/20/2022 Date
5.59(c) 5.52(c) 5.02(c) 5.05(c) 4.98 Last
116 577 503 632 306 410 227 865 160 331 Volume
-3.79% -1.25% -9.06% +0.60% -1.39% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 - - -
Net income 2021 -128 M - -
Net cash position 2021 3,59 M - -
P/E ratio 2021 -2,10x
Yield 2021 -
Sales 2022 - - -
Net income 2022 -137 M - -
Net cash position 2022 79,8 M - -
P/E ratio 2022 -2,25x
Yield 2022 -
Capitalization 266 M 266 M -
EV / Sales 2021 -
EV / Sales 2022 -
Nbr of Employees 90
Free-Float -
More Financials
Company
Evelo Biosciences, Inc. is a biotechnology company. The Company is focused on discovering and developing a class of orally delivered medicines that act on cells in the small intestine with systemic therapeutic effects. Its product candidates are pharmaceutical preparations of single strains of microbes or microbial extracellular vesicles selected for their ability to modulate the immune system through SINTAX, the... 
More about the company
Ratings of Evelo Biosciences, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
C-
More Ratings
All news about EVELO BIOSCIENCES, INC.
01/17Evelo Biosciences Presents Data on EDP1815 Mechanism of Action and Supporting Ongoing C..
GL
01/17Evelo Biosciences Presents Data on EDP1815 Mechanism of Action and Supporting Ongoing C..
GL
01/17Evelo Biosciences Presents Data on EDP1815 Mechanism of Action and Supporting Ongoing C..
CI
01/04EVELO BIOSCIENCES, INC. : Change in Directors or Principal Officers, Financial Statements ..
AQ
01/04Evelo Biosciences Announces Key 2022 Strategic Priorities and Upcoming Catalysts
GL
01/04Evelo Biosciences Announces Key 2022 Strategic Priorities and Upcoming Catalysts
GL
2021EVELO BIOSCIENCES, INC. : Other Events (form 8-K)
AQ
2021Evelo Biosciences, Inc. Announces Updates of Phase 2 Clinical Trial of EDP1815 in Atopi..
CI
2021EVELO BIOSCIENCES, INC.(NASDAQGS : EVLO) added to NASDAQ Biotechnology Index
CI
2021Evelo Biosciences Added to Nasdaq Biotechnology Index
AQ
2021Evelo Biosciences to Present at 2021 Jefferies London Healthcare Conference
GL
2021JMP Securities Adjusts Price Target on Evelo Biosciences to $41.50 From $44, Maintains ..
MT
2021Evelo Biosciences Shares Rise on Chardan Upgrade
MT
2021Chardan Upgrades Evelo Biosciences to Buy From Neutral on Valuation, Keeps $12 Price Ta..
MT
2021EVELO BIOSCIENCES, INC. Management's Discussion and Analysis of Financial Condition an..
AQ
More news
News in other languages on EVELO BIOSCIENCES, INC.
01/17Evelo Biosciences présente des données sur le mécanisme d'action de l'EDP1815 et soutie..
2021Evelo Biosciences, Inc. Annonce des mises à jour de l'essai clinique de phase 2 de l'ED..
2021Les actions d'Evelo Biosciences augmentent suite à la mise à niveau de Chardan
2021Le candidat-médicament pour le psoriasis d'Evelo Biosciences réduit la gravité dans un ..
2021Evelo Biosciences obtient un brevet couvrant les formulations de la bactérie Veillonell..
More news
Analyst Recommendations on EVELO BIOSCIENCES, INC.
More recommendations
Chart EVELO BIOSCIENCES, INC.
Duration : Period :
Evelo Biosciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EVELO BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 4,98 $
Average target price 21,25 $
Spread / Average Target 327%
EPS Revisions
Managers and Directors
Balkrishan Gill President, Chief Executive Officer & Director
Luca Scavo Chief Financial Officer, Treasurer & Senior VP
David R. Epstein Chairman
Mark W. Bodmer Chief Scientific Officer, President-R&D
Duncan McHale Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
EVELO BIOSCIENCES, INC.-16.80%270
GILEAD SCIENCES, INC.-4.88%86 640
REGENERON PHARMACEUTICALS-2.12%64 627
VERTEX PHARMACEUTICALS5.12%58 692
WUXI APPTEC CO., LTD.-6.39%51 406
BIONTECH SE-37.29%39 044